# Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

> **NCT01038739** · PHASE3 · TERMINATED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 330 (actual)

## Conditions studied

- Diverticulitis

## Interventions

- **DRUG:** Mesalazine
- **DRUG:** Mesalazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01038739
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 330 (ACTUAL)
- **Why stopped:** Stopped due to futility.
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01038739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01038739, "Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT01038739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*